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Germline mutations in genes encoding proteins involved in DNA mismatch repair are responsible for the autosomal dominantly
inherited cancer predisposition syndrome hereditary nonpolyposis colorectal cancer (HNPCC). We describe here analysis of hMLH1
and hMSH2 in nine Greek families referred to our centre for HNPCC. A unique disease-causing mutation has been identified in seven
out of nine (78%) families. The types of mutations identified are nonsense (five out of seven) (hMLH1: E557X, R226X; hMSH2:
Q158X, R359X and R711X), a 2bp deletion (hMSH2 1704_1705delAG) and a 2.2kb Alu-mediated deletion encompassing exon 3
of the hMSH2 gene. The majority of mutations identified in this cohort are found in hMSH2 (77.7%). Furthermore, four of the
mutations identified are novel. Finally, a number of novel benign variations were observed in both genes. This is the first report of
HNPCC analysis in the Greek population, further underscoring the differences observed in the various geographic populations.
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Hereditary nonpolyposis colorectal cancer (HNPCC) is the most
common inherited syndrome predisposing to colorectal cancer
(CRC), accounting for 5–10% of the total CRC (Lynch and de la
Chapelle, 1999; MIM 114500). Hereditary nonpolyposis colorectal
cancer is characterised by early-onset CRC (mean age at diagnosis
B45 years) and an increased incidence of cancer in other organs
such as the endometrium, stomach, small bowel, ovary, hepato-
biliary tract, renal pelvis and ureter (Watson and Lynch, 1993;
Lynch and de la Chapelle 1999).
Hereditary nonpolyposis colorectal cancer segregates in an
autosomal dominant manner and it is caused by germline
mutations in a group of genes encoding proteins involved in the
DNA mismatch repair (MMR) pathway. At least five genes of the
pathway, namely hMLH1, hMSH2, hMSH6, hPMS1 and hPMS2,
have been implicated in HNPCC (Leach et al, 1993; Papadopoulos
and Lindblom, 1997; Peltoma ¨ki and Vasen, 1997). However, the
majority of mutations (B90%) have been identified in hMLH1
(B50%) and hMSH2 (B40%). Germline mutations that have been
identified in hMLH1 and hMSH2 are scattered throughout the
coding regions of the two genes with no obvious phenotype–
genotype correlation. The majority of mutations identified are
small insertions/deletions leading to frameshifts and truncated
protein products. In addition, a large number of nonsense
mutations have been identified (Peltoma ¨ki and Vasen, 1997). In
recent years, an increasing number of reports have shown that
B10–30% of mutations responsible for HNPCC are large genomic
rearrangements affecting one or more exons of the two genes
(Wijnen et al, 1998; Gille et al, 2002; Wagner et al, 2003). This, in
addition to the genetic heterogeneity and clinical variability among
HNPCC families, makes identification of germline mutations in
families suspected to suffer by HNPCC laborious and time
consuming. Use of tissue microarray immunohistochemistry
expression analysis can help pinpoint the affected gene thereby
targeting mutation screening directly to that gene, cutting down on
cost and time of analysis (Hendriks et al, 2003; Jourdan et al, 2003;
Hardisson et al, 2003). However, characterisation of the disease
causing mutation in afflicted families is essential as it allows
identification of carrier relatives, who may require appropriate
surveillance and alleviates noncarrier individuals from costly and
intrusive surveillance.
MATERIALS AND METHODS
Patients
To date, 64 individuals from 28 Greek families with CRC were
referred to our centre through the Oncology and Gastroenterology
Departments of the Diagnostic and Therapeutic Center of Athens
HYGEIA and other hospitals throughout Greece. Following an
interview with as many family members as possible, a detailed
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sfamily tree is constructed. This is then reviewed by three
independent scientists in the laboratory in order to make a
decision on the risk of the family to be affected by HNPCC. Based
on the Amsterdam II (Vasen et al, 1999) and/or Bethesda Criteria
(Rodriguez-Bigas et al, 1997), nine of the 28 families were selected
for molecular analysis of hMLH1 and hMSH2. The study
population, therefore, consisted of seven Amsterdam positive
families, one Bethesda positive and one family who did not meet
the criteria but were included due to the clustering of CRC.
Screening has been completed in 30 individuals from nine
families. Testing was initially carried out on DNA from an affected
family member and upon detection of an inactivating mutation the
rest of the family members were directly tested for this mutation.
Due to the large proportion of genomic rearrangements that
have been shown to be responsible for HNPCC, analysis is initially
carried out using multiplex ligation-dependent probe amplification
(MLPA) for screening for such mutations in hMLH1 and hMSH2.I f
a genomic rearrangement is not detected then PCR for all exons
and splice junctions of the two genes is carried out. Screening for
point mutations and small insertions/deletions is carried out in the
majority of amplicons using denaturing high-performance liquid
chromatography (dHPLC). Denaturing high-performance liquid
chromatography is not carried out for exons containing poly-
morphic repeats, that is, hMLH1 exon 12 and hMSH2 exons 2 and
5. These three exons and all those indicated by an abnormal
dHPLC elution profile are subjected to cycle sequencing.
DNA and RNA isolation
Genomic DNA and RNA were purified from peripheral blood
leukocytes or tissue using standard extraction protocols.
Multiplex ligation-dependent probe amplification (MLPA)
Multiplex ligation-dependent probe amplification was carried out
using the P003 MSH2/MLH1 kit (MRC-Holland, Netherlands) as
instructed by the manufacturer. Fragment analysis was carried out
on the ABI Prism
s 310 Genetic Analyzer using TAMRA-500 as size
standard. A peak pattern of 42 peaks ranging in size from 130 to
472nt is obtained (Gille et al, 2002).
PCR amplification
The complete coding sequence of hMLH1 and hMSH2 inclu-
ding splice junctions was amplified by PCR. Primers used have
been described by others (Holinski-Feder et al, 2001). Reactions
of 50ml were heated on a PTC-200 MJ Research Thermocycler
(MJ Research Inc, USA) at 951C for 5min then cycled 35 times
of denaturation at 951C for 40s, annealing at the appropriate
temperature for 30s and extension at 721C for 30–60s, followed
by a final extension step at 721C for 6min. Reaction mixture
was 20mM Tris HCl (pH 8.4), 50mM KCl, 1.5mM Mg
2þ, 200mM
each dNTP, 1.5U Taq DNA polymerase (Invitrogen, UK) or 2.5
UOptimase polymerase (Transgenomic) and 15pmol of each
primer.
Denaturing high-performance liquid chromatography
analysis
The WAVE DNA Fragment Analysis System (Transgenomic, Inc,
USA) and associated WAVE-Makert software were used as
previously described (Mihalatos et al, 2003a).
Table 1 Variants identified in the hMLH1 and hMSH2 genes during this study
Gene Family ID Risk status
a MSI Exon Nucleotide Effect Types of cancer
Mutation
hMLH1 3335 Amsterdam 4/5 15 1669G4T
b E557X CRC
c, melanoma, liver, TCC
d,
endometrium, lung
5838 Amsterdam NT 8 676C4T R226X CRC
c, endometrium, larynx, stomach
hMSH2 7562 Amsterdam 0/5 3 Del
e 2.2kb Protein missing
aa 123–215
CRC
c, endometrium
8344 Bethesda 4/5 3 472C4T
b Q158X CRC
c
8902 Amsterdam 5/5 13 2131C4T R711X CRC
c, ovaries, endometrium
9663 Amsterdam NT 11 1704_1705del
e
AG
b
Fs
f resulting
in STOP at
codon 570
CRC
c, endometrium
10107 Amsterdam NT 6 1076G4T
b R359X CRC
c, ovary, endometrium, urinary
tract, eye, prostate, melanoma, breast
Gene Exon Codon
Nucleotide
change Consequences No. of families
Benign polymorphisms
hMLH1 IVS 4 309 30
b c4a —2
Exon 8 219 655A4G I219V 5
Exon 12 464
b 464T4C P464P
IVS 12 1408 54
b c4t— 2
IVS 13 1558 13 g4a— 2
IVS 14 1668 19 a4g6
hMSH2 IVS 1 211+9 c4g— 1
Exon 4 224
b 669C4T L224L 2
IVS 9 1511 9a 4t— 1
IVS 10 1661+13 g4a— 2
IVS 12 2006 6t 4c— 2
aRisk status based on the Amsterdam II (Vasen et al, 1999) and Bethesda (Rodrigues – Bigas et al, 1997) criteria.
bNovel variations identified in this study (marked in bold).
cCRC¼colorectal cancer.
dTCC¼transitional cell carcinoma.
eDel¼deletion.
fFs¼frame shift mutation.
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Purification of the PCR products was performed using the Concert
Rapid PCR purification or gel extraction system kits (Marligen
Biosciences Inc, USA). Automated cycle sequencing for both
strands was performed with the ABI Prism
s 310 Genetic Analyzer
using the BigDye Terminator Cycle Sequencing kit. Sequences
obtained were aligned, using Sequencher
s PC software
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and ENSEMBL (hMLH1: AY217549; hMSH2: ENSEMBL
ENST00000233146) and examined for the presence of mutations.
All nucleotide numbers refer to the wild-type cDNA.
Long PCR
The deletion in hMSH2 exon 3 was confirmed by long PCR using
the Expand High Fidelity PCR System (Roche, Germany) according
to the manufacturer’s instructions. PCR products were separated
by agarose gel electrophoresis and visualised by EtBr staining.
RT–PCR
Total RNA was extracted from peripheral blood leukocytes of
patients from family D using Trizol (Life Technologies, UK),
according to the manufacturer’s instructions. First-strand syn-
thesis was performed by denaturing approximately 500–1000ng
total RNA and random hexamers (5mM final concentration) for
4min at 701C, followed by snap freezing on ice and addition of
dNTPs (0.5mM final concentration), 1Uml
 1 recombinant RNase
inhibitor (Invitrogen, UK) and 200U MMLV reverse transcriptase
(Invitrogen, UK). The mixture was incubated at 371C for 1h
followed by denaturation of the enzymes at 951C for 5min. In total,
4ml of cDNA were used for subsequent PCR amplification.
RESULTS
To date, 30 individuals from nine Greek families at high risk of
having HNPCC, have been screened to our centre for genetic
testing. Of these, MSI analysis was carried out in six patients for
whom matching normal and tumour tissue was available.
Our strategy is based on an initial screening of genomic DNA for
large genomic rearrangements of hMLH1 and hMSH2 using the
recently described method MLPA (Schouten et al, 2002). If a
rearrangement is not detected, PCR amplification of all exons and
splice junctions of the two genes is carried out, using primers
previously described by others (Holinski-Feder et al, 2001). For the
majority of amplicons, dHPLC is used as a mutation screening test,
followed by direct sequencing for characterisation of mutations
indicated by dHPLC. Denaturing high-performance liquid chro-
matography was not carried out for amplicons containing
repetitive polymorphic sequences, that is, exon 12 of hMLH1 and
exons 2 and 5 of hMSH2.
In seven families (3335, 5838, 7562, 8344, 8902, 9663 and 10107
in Table 1), seven different mutations have been identified. Four of
the mutations are novel nonsense mutations in the hMLH1 and
hMSH2 genes. One family (7562 in Table 1) carries a 2.2kb
deletion encompassing exon 3 of the hMSH2 gene while the
remaining two identified mutations have already been described in
the ICG-HNPCC database (http://www.nfdht.nl (ICG-HNPCC
mutation database).
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Figure 1 Pedigrees of families investigated for germline mutations of the hMLH1 and hMSH2 genes. Grey symbols indicate individuals with cancer. The
proband is indicated by an arrow. A black circle inside a symbol indicates individuals found to carry the mutation. N¼individual tested for the family
mutation and was found to be of normal genotype. CRC¼colorectal cancer, CaEn¼endometrial cancer, CaLi¼liver cancer, CaLu¼lung cancer,
TCC¼transitional cell carcinoma, CaNP¼nasopheryngeal cancer, CaSt¼stomach cancer, CaOv¼ovarian cancer, CaEy¼cancer of the eye,
CaPr¼prostate cancer, poss.¼possibly, CaLa¼cancer of the larynx, CaGe¼‘gynaecological’ cancer, CaRe¼cancer of the rectum.
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In family 3335 (Figure 1A and Table 1), the identified mutation is a
single base substitution in exon 15 of the hMLH1 gene. The
mutation, 1669G4T (Figure 3A), converts the glutamine at codon
557 to a STOP codon. The mutation was originally identified in a
patient (III:20,Figure 1A and 2A) who had transitional cell
carcinoma and CRC. Tumours of this patient were found to be
MSI positive. MSI analysis of polyps resected from the patient’s
brother (III:18 Figure 1A) was negative. Individual III:18 has not
developed a malignancy until the age of 65. Mutation analysis of
hMLH1 exon 15 revealed that he did not carry the mutation
identified in his brother. The mutation was however identified in
two more patients of this family (III:14 and III:8, Figure 1A). In the
first patient a malignant melanoma had been diagnosed while the
latter suffered from CRC.
In family 8344 (Figure 1B, Table 1), a mutation was suggested by
dHPLC in the amplicon encompassing exon 3 of the hMSH2 gene
(Figure 2B). The mutation was shown by sequencing to be a C4T
substitution of nt 472 of the cDNA (Figure 3B) and results in
substitution of a glutamine at position 158 by a STOP codon. The
mutation was identified in a patient who was diagnosed with CRC
at the age of 38. His sister, who was also shown to carry the
mutation developed a polyp of the large intestine at the age of 27.
Their brother, who at the age of 37 is asymptomatic was found not
to carry the family mutation.
In family 9663 (Figure 1C, Table 1), the proband (II:6, Figure 1C)
was diagnosed with endometrial cancer at the age of 52 and CRC at
65. Her father (I:2, Figure 1C), brother (II:2, Figure 1C) and son
(III:3, Figure 1C) also suffered from CRC while her niece (III:1,
Figure 1C) died from endometrial cancer at the age of 34.
Denaturing high-performance liquid chromatography analysis
revealed a mutation in exon 11 of hMSH2. Sequencing showed
this to be a 1704_1705delAG, which results in frameshift and
creates a stop codon at 570 (Figure 3C). The mutation was also
identified in the proband’s son (III:3, Figure 1C), and one of her
daughters (III:6, Figure 1C) who at the age of 44 is asymptomatic.
The patient from family 10107 (Figure 1D, Table 1) was first
diagnosed with cancer of the ovaries at the age of 25, followed by
endometrial cancer at 36, cancer of the urinary tract at 57 and CRC
at 59. In addition, there were other cases of CRC, cancer of the eye,
breast, endometrium, prostate and melanoma in the family.
Sequencing of exon 6 of hMSH2 revealed a G4T substitution at
the last base of the exon (nt 1076). In order to confirm the effect of
this mutation, that is, whether it results in a splicing defect or
substitution of the amino acid by a stop codon, RT–PCR and
sequencing was carried out. These showed that the mutation
results in substitution of an arginine residue by a stop codon at 359
(Figure 3D). No other family members were available for analysis.
Large genomic rearrangements
In family 7562 (Figure 1E, Table 1), MLPA analysis for screening of
large genomic rearrangements revealed a deletion comprising exon
3 of the hMSH2 gene. Long-range PCR using primers located in
introns 2 and 4 (Figure 4) confirmed the deletion, which was found
to be 2.2kb long (Figure 4B). Subsequent fine mapping of the
deletion breakpoints using a mixture of restriction endonucleases
(Figure 4C) allowed the design of a new primer suitable for
sequencing of the breakpoints. These were shown to be located in
two Alu repeats in introns 2 (AluSg) and 3 (AluSx), respectively,
sharing 78% homology. The deletion was flanked by 21 bases of
complete homology. It is an in-frame deletion and results in the
absence of 93 aa residues from the resulting protein product. The
proband was a female patient who was diagnosed with CRC at the
age of 35. The patient’s father had died from CRC, her sister was
diagnosed with endometrial cancer at the age of 45 and her brother
developed CRC at the age of 42. The mutation was later identified
in the siblings of the patient and in her daughter who at the age of
29 years is an asymptomatic carrier. MSI analysis of tumour DNA
from the proband was found to be negative.
Families with known mutations
In family 5838 (Figure 1F, Table 1), 676C4T was identified by
sequencing in exon 8 of the hMLH1 gene. The mutation results in
the substitution of an arginine codon at position 226 by a stop
codon and has previously been described by others (Moslein et al,
1996; Wehner et al, 1997). It was originally identified in a patient
who had been diagnosed with CRC at the age of 49 (IV:1 in
Figure 1F) who came from a family with multiple cases of CRC, two
cases of endometrial cancer, both of whom carry the mutation, in
addition to cancer of the larynx and the stomach.
In family 8902 (Figure 1G, Table 1), there were three cases of
CRC, three cases of gynaecological cancers and one individual for
whom no information of cancer type was available. Denaturing
high-performance liquid chromatography analysis identified a
mutation in exon 13 of the hMSH2 gene, whose sequencing was
shown to be C4T mutation at nucleotide 2131, resulting in
substitution of the arginine at codon 711 by a stop codon. This
mutation has been previously described by others (Kurzawski et al,
2002).
DISCUSSION
In this study we present mutation analysis of the hMLH1 and
hMSH2 genes implicated in the HNPCC syndrome in a cohort of
nine Greek families at high risk of having HNPCC. Two of the
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Family 8344 (Figure 1B) meets the Bethesda criteria since cancer
was diagnosed in the proband at the age of 38. Family 9659
(Figure 1I) was included in the analysis due to the number of
affected members (four individuals with CRC and one case of
endometrial cancer). The pathogenic mutation was identified in
seven out of nine (78%) families, including also one of the non-
Amsterdam families (8344). This percentage compares well with
other studies (Caluseriu et al, 2001; Wagner et al, 2003). However,
it should be stressed that the accuracy and reliability of family
history provided by patients and their relatives may not always be
accurate and may therefore misguide researchers in the assign-
ment of a family into a particular risk status group.
Interestingly, the majority of mutations (five out of seven, i.e.
77.7%) identified in this study are located in the hMSH2 gene.
Although our sample group is quite small, this finding is in
contrast with previous studies where the majority of pathogenic
mutations associated with HNPCC have been identified in hMLH1
(Peltoma ¨ki and Vasen, 1997; Wagner et al, 2003). Furthermore,
four of the six single-point substitutions/small deletions are novel
mutations, not previously described in the ICG-HNPCC mutation
database (http://www.nfdht.nl). All single-point substitutions/
small deletions identified in this study are predicted to introduce
premature stop codons in the gene sequence, therefore, resulting
in truncated protein products. One of the novel mutations occurs
at the last base of exon 6 of the hMSH2 gene. The effect of this
mutation on the protein was further investigated using RT–PCR
and sequencing, showing that the mutation results in substitution
of an arginine residue by a stop codon at 359. This, in addition to,
segregation of these novel mutations with the disease phenotype in
the majority of cases confirms their pathogenic nature. One
individual in each of the families, 7562, 8902 and 9663 in Table 1,
was found to be an asymptomatic carrier. However, all three
individuals are relatively young, 29, 14 and 44, respectively, while
the average age at onset of the disease is quoted as being B45
years of age according to the Amsterdam II criteria (Vasen et al,
1999). Furthermore, the lifetime risk of developing CRC in carriers
of an MMR gene mutation is B80% (Vasen et al, 1996; Aarnio et al,
1999).
The mutations identified in this and other studies are scattered
throughout the two genes, with no obvious phenotype–genotype
correlation. This, in addition to identification of both single-point
substitutions and small deletions, as well as a 2.2kb deletion,
necessitates screening of the entire genes both for single-point
mutations and small insertions/deletions as well as large genomic
rearrangements. Even in this small cohort of patients genomic
rearrangements account for 14.2% of identified mutations. Our
results, therefore, indicate the importance of applying a variety of
1 3M 1 M2
2.2 kb
1.6 kb
0.6kb
4.4kb
2.2 kb
M1 2 4 6 8
2.2 kb
3F 3R 4R 2F
357 9
2 4
A
B
C
Exon 2
130
H B
324
Exon 3
4362
1621
Exon 4
H E
262 225 1004 793
Figure 4 Characterisation of the 2.2kb deletion identified in family 7562. (A) Schematic representation (not to scale) of the fragment of hMSH2 gene
amplified by long PCR showing the position of primers (horizontal arrows), exons (empty boxes), restriction endonuclease cleavage sites (vertical bars:
H¼HindIII, E¼EcoRI, B¼BglII) and the deletion. (B) Long-range PCR using combinations of primers (from A) spanning the repeat. M¼molecular weight
marker (VII, Boehringer Manheim, Germany), lanes 1–3 using primers 2F and 3R, 1¼normal DNA, 2–3¼patient DNA; lanes 4–6 using primers 3F and 4R,
4¼normal DNA, 5–6¼patient DNA; lanes 7–9 using primers 2F and 4R, 7¼normal DNA, 8–9¼patient DNA. (C) Restriction endonuclease digestion
of PCR products from B with HindIII, EcoRI and BglII. The bands containing exon 3 (2.3kb in lane 1 and 1.6kb in lane 2) have disappeared and a new band
0.6kb in length resistant to digestion with any of the three enzymes appears in the mutant sample (lanes 3 and 4). 1: normal control digested with EcoRI/
HindIII/BglII. 2: normal control digested with EcoRI/HindIII. 3: patient DNA digested with EcoRI/HindIII/BglII. 4: patient DNA digested with EcoRI/HindIII. Lane
M1: molecular weight marker V (Boehringer Manheim, Germany). Lane M2: Molecular weight marker 100bp (New England Biolabs).
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mutations in high-risk patients.
Another interesting point emerging from our study of Greek
HNPCC families is that a unique mutation was identified in each
kindred. This is in contrast to other populations such as the
Finnish where two mutations account for 450% of the HNPCC
families (Nystrom-Lahti et al, 1995).
Clinical diagnosis of HNPCC is not always easy as there is no
clear phenotype associated with the disorder as is the case with
other cancer predisposition syndromes such as familial adenoma-
tous polyposis (Mihalatos et al, 2003b). Besides the spectrum of
cancers characteristic of HNPCC, MSI is considered as one of the
hallmark diagnostic features of HNPCC-related cancers (Boland
et al, 1998). However, in this study, a pathogenic mutation was
identified in the hMSH2 gene in a patient whose CRC tumour was
found to be microsatelite stable (family 7562). This could be
explained by the absence of enough cancerous material in the
sample analysed. However, if MSI analysis were a strict criterion in
the inclusion of patients for genetic analysis, this patient would
have been excluded. This finding stresses the need for use of a
combination of criteria in the selection of patients suitable for
mutation screening.
The reason for the interfamilial variability in the phenotypic
manifestation of HNPCC is still not clear. However, use of
DNA microarray analysis should soon shed some light as to the
genetic factors that may act as modifiers in the disease
phenotype predicted by the detection of germline mutations in
MMR genes.
In summary, we have analysed nine families at high risk of
carrying mutations in one of the MMR genes. The pathogenic
mutation was identified in seven of the families. Three of the
mutations identified are novel single base nonsense mutations,
while a novel small deletion also resulting in premature termina-
tion has been identified. Finally, two previously described
nonsense mutations and a 2.2kb deletion in hMSH2 were also
identified. The results presented here provide the spectrum of
mutations responsible for HNPCC for the first time in the Greek
population, underscoring the differences observed in different
geographic populations.
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